Ruoyu Liu^1,#, Yuhao Hu^1,#, Jing Xu², Aiting Cai¹, Anqi Wu¹, Lin Chen³, Weihua Cai³, Deping Dong⁴, Henggui Xu^5,*, Feng Wang^1,*

Oncologie, Vol.23, No.3, pp. 303-320, 2021, DOI:10.32604/oncologie.2021.018514

Abstract Cancers are diseases with a high mortality rate worldwide. In order to better diagnose and improve the survival rate, many studies have been conducted. In recent years, the role of non-coding RNAs in cancers has been confirmed, and circular RNAs (circRNAs) have attracted much attention. CircRNAs are involved in the occurrence and development of cancers with high stability. Experiments have shown that they can exist stably in peripheral blood. Therefore, the expression of circulating circRNAs can be detected to help diagnose cancers and reflect tumor progression. In this review, we summarized the role of circulating circRNAs in cancers and discussed… More >

D. Grazziotin-Soares, J.-P. Lotz

Oncologie, Vol.21, No.1, pp. 49-51, 2019, DOI:10.3166/onco-2019-0037

Abstract This article has no abstract. More >

A. de Nonneville, A. Gonçalves

Oncologie, Vol.21, No.1, pp. 33-39, 2019, DOI:10.3166/onco-2019-0039

Abstract Triple-negative breast cancer (TNBC), defined by the lack of expression of hormone receptors and HER2 (Human Epidermal growth factor Receptor-2), accounts for 15–20% of breast cancers. However, this definition, which is essentially negative, masks the large biological heterogeneity of this subtype. While chemotherapy is the main established systemic treatment in both early and advanced stages of the disease, the progressive understanding of the molecular components involved in the pathogenesis of TNBC allows innovative therapeutic perspectives. The objective of this review is to describe these potential targets and to explore current and future treatments that will help fighting this cancer with… More >

Pierre-Guillaume Poureau^1,2,*, Jean-Philippe Metges²

Oncologie, Vol.23, No.1, pp. 47-59, 2021, DOI:10.32604/Oncologie.2021.15525

Abstract Immunotherapy for digestive cancers is booming and for the first time an immune checkpoint inhibitor has been granted marketing authorization for the treatment of digestive cancer. In order to better understand the mecanism of action of these treatments, their adverse events and the escape mecansim, it is necessary to know the fundamentals of cancer immunology. The innate and adaptive immune system allows the elimination of cancer cells by direct non-specific cytotoxicity (Natural Killer cells), by the development of an adaptive cell-mediated response (dendritic cells becoming antigen presenting cells, allowing the differentiation of lymphocytes naive in CD4 and CD8 T lymphocytes)… More >

Neslihan Duzkale^1,*, Hikmet Taner Teker²

Oncologie, Vol.22, No.2, pp. 65-74, 2020, DOI:10.32604/oncologie.2020.013707

Abstract BRCA1/2 genes are responsible for the hereditary breast and ovarian cancer syndrome. In this study, Turkish women with ovarian cancer were investigated in terms of demographic, clinicopathologic and family cancer stories according to their condition of the BRCA1/2 genes mutation carrier. During 2011 to 2017 in Turkey, BRCA1 and BRCA2 genes were analyzed in 38 women, who were diagnosed with cancer using Next Generation Sequencing technique. Pathogenic mutations were detected in 9 (23.7%) of patients. The diagnosis age for Ovarian cancer patients for BRCA1/2 mutation carriers was found higher. It was seen that mutations mostly occurred in the BRCA2 gene… More >

Mian LIU¹, Xumeng ZHANG^{2, *}

BIOCELL, Vol.41, No.1, pp. 19-26, 2017, DOI:10.32604/biocell.2017.41.019

Abstract Bladder, kidney, prostate and testicular carcinoma are the top four genitourinary cancers in China. Here we analyzed mRNA and miRNA expression profiles of carcinomas of the bladder (TCC), kidney (ccRCC) and testis (TGCT) to uncover their specific regulatory mechanisms. The gene expression profiles of GSE31617 were downloaded from GEO database, which contained 27 samples, including 10 TCC, 7 TGCT and 10 ccRCC. Specific up- and downregulated differentially expressed genes (DEGs) and differentially expressed microRNAs (DEmiRNAs) of each cancer were selected and target genes of DEmiRNAs were predicted. Gene interaction network of the shared genes and target genes of DEmiRNAs of… More >